Isabella Hofer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Isabella Hofer has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Anne Vincent-Salomon
Institut Curie, PSL University
58 shared publications - Arianna Mencattini
Department of Electronic Engineering, University of Rome Tor Vergata, Rome, Italy
58 shared publications - Christophe Le Tourneau
Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France
58 shared publications - Claire Bonneau
Institut Curie, Department of Gynecology, Saint-Cloud, France
58 shared publications - Constance Lamy
Department of Drug Development and Innovation (D3i), Institut Curie, Paris-Saclay University 1
58 shared publications - Eugenio Martinelli
Department of Electronic Engineering, University of Rome Tor Vergata, Rome, Italy
58 shared publications
Latest Publications
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Video S2 from An Extracellular Matrix–Producing Subset of Cancer-Associated Fibroblasts Drives Chemoresistance in Breast Cancer via SRC Activation and G0S2 Upregulation
ToC mono-culture of MDA-MB-231, time length 72h, 2μM Doxorubicin. Scale bar = 100 μm.
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessVideo S2 from An Extracellular Matrix–Producing Subset of Cancer-Associated Fibroblasts Drives Chemoresistance in Breast Cancer via SRC Activation and G0S2 Upregulation
ToC mono-culture of MDA-MB-231, time length 72h, 2μM Doxorubicin. Scale bar = 100 μm.
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Figure 7 from An Extracellular Matrix–Producing Subset of Cancer-Associated Fibroblasts Drives Chemoresistance in Breast Cancer via SRC Activation and G0S2 Upregulation
ECM-myCAFs induce SRC kinase activity in TNBC cells. A, Kinome tree depicting upregulation and downregulation of kinase family activities in MDA-MB-231 cells upon 42 hours of ECM-myCAF transwell coculture (n = 2 different patient-derived ECM-myCAFs). B, Western blot showing pSRCTyr416, total SRC, G0S2, and β-actin protein levels in MDA-MB-231 cells after 42 hours of transwell culture without or with ECM-myCAFs (n = 4 different patient-derived ECM-myCAFs). C and D, Quantification of pSRC and G0S2 levels from B. pSRC and G0S2 protein levels in MDA-MB-231 in coculture with ECM-myCAF are normalized to their respective protein levels in monoculture. Values are represented as the mean ± SEM. E, Venn diagram showing the overlap between TFs predicted to be activated in MDA-MB-231 cells upon ECM-myCAF coculture in ToC and those known to positively regulate G0S2 transcription (as shown in Fig. 5F), together with TFs identified by Ji and colleagues (62) as regulated by v-SRC. F, Western blot showing pSRC, total SRC, G0S2, and β-actin protein levels at indicated time points in MDA-MB-231 cells silenced (siG0S2) or not (siCTRL) for G0S2. G, Quantification of F. pSRC level was normalized to siCTRL at 48 hours. H, Representative Western blot of MDA-MB-231 cells after treatment with increasing concentrations of the SRC family kinases inhibitor dasatinib. I, Quantification of G0S2 protein levels upon 48 hours of dasatinib (50 nmol/L) treatment normalized to DMSO control (n = 2 independent experiments). Values are represented as the mean ± SEM. J, Automated quantification of MDA-MB-231 survival ± ECM-myCAFs ± doxorubicin ± dasatinib (n = 3 independent experiments using three different patient-derived ECM-myCAFs; n = 3 videos analyzed per condition). C, D, and I, Statistical significance was assessed by the Mann–Whitney test; J,P values from two-sided Wilcoxon rank-sum test. E, Created in BioRender. Mechta-Grigoriou, F. (2025) https://BioRender.com/l3pzirw.
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 7 from An Extracellular Matrix–Producing Subset of Cancer-Associated Fibroblasts Drives Chemoresistance in Breast Cancer via SRC Activation and G0S2 Upregulation
ECM-myCAFs induce SRC kinase activity in TNBC cells. A, Kinome tree depicting upregulation and downregulation of kinase family activities in MDA-MB-231 cells upon 42 hours of ECM-myCAF transwell coculture (n = 2 different patient-derived ECM-myCAFs). B, Western blot showing pSRCTyr416, total SRC, G0S2, and β-actin protein levels in MDA-MB-231 cells after 42 hours of transwell culture without or with ECM-myCAFs (n = 4 different patient-derived ECM-myCAFs). C and D, Quantification of pSRC and G0S2 levels from B. pSRC and G0S2 protein levels in MDA-MB-231 in coculture with ECM-myCAF are normalized to their respective protein levels in monoculture. Values are represented as the mean ± SEM. E, Venn diagram showing the overlap between TFs predicted to be activated in MDA-MB-231 cells upon ECM-myCAF coculture in ToC and those known to positively regulate G0S2 transcription (as shown in Fig. 5F), together with TFs identified by Ji and colleagues (62) as regulated by v-SRC. F, Western blot showing pSRC, total SRC, G0S2, and β-actin protein levels at indicated time points in MDA-MB-231 cells silenced (siG0S2) or not (siCTRL) for G0S2. G, Quantification of F. pSRC level was normalized to siCTRL at 48 hours. H, Representative Western blot of MDA-MB-231 cells after treatment with increasing concentrations of the SRC family kinases inhibitor dasatinib. I, Quantification of G0S2 protein levels upon 48 hours of dasatinib (50 nmol/L) treatment normalized to DMSO control (n = 2 independent experiments). Values are represented as the mean ± SEM. J, Automated quantification of MDA-MB-231 survival ± ECM-myCAFs ± doxorubicin ± dasatinib (n = 3 independent experiments using three different patient-derived ECM-myCAFs; n = 3 videos analyzed per condition). C, D, and I, Statistical significance was assessed by the Mann–Whitney test; J,P values from two-sided Wilcoxon rank-sum test. E, Created in BioRender. Mechta-Grigoriou, F. (2025) https://BioRender.com/l3pzirw.
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Video S11 from An Extracellular Matrix–Producing Subset of Cancer-Associated Fibroblasts Drives Chemoresistance in Breast Cancer via SRC Activation and G0S2 Upregulation
ToC mono-culture of MDA-MB-436, time length 72h, 1μM Paclitaxel. Scale bar = 100 μm.
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessVideo S11 from An Extracellular Matrix–Producing Subset of Cancer-Associated Fibroblasts Drives Chemoresistance in Breast Cancer via SRC Activation and G0S2 Upregulation
ToC mono-culture of MDA-MB-436, time length 72h, 1μM Paclitaxel. Scale bar = 100 μm.
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Figure 3 from An Extracellular Matrix–Producing Subset of Cancer-Associated Fibroblasts Drives Chemoresistance in Breast Cancer via SRC Activation and G0S2 Upregulation
Primary ECM-myCAFs display a heterogeneous response to doxorubicin. A and B, Representative images of ECM-myCAFs from patient #2 (A) and patient #3 (B) ± doxorubicin at acquisition start (0 hours) and 72 hours after culture in ToC. Scale bar, 100 μm. White arrows, living cells; red arrows, dead cells. C, ECM-myCAF (from three different patients) apoptosis rate ± MDA-MB-231 ± doxorubicin (n = 3 independent experiments; n = 3 videos per condition). D, Alive ECM-myCAF (from three different patients) ± MDA-MB-231 ± doxorubicin normalized to alive cells at acquisition start (0 hours; n = 3 independent experiments; n = 3 videos per condition). E and F, ECM-myCAF apoptosis rate and alive cells (combining the three patients) ± MDA-MB-231 ± doxorubicin. G, Representative images of ECM-myCAFs under paclitaxel treatment at acquisition start (0 hours) and 72 hours after culture in ToC. Scale bar, 100 μm. White arrows, living cells; red arrows, dead cells. H, Manual quantification of ECM-myCAF apoptosis rate (combining three patients) ± MDA-MB-231 ± paclitaxel. I, Alive ECM-myCAF (combining three patients) ± MDA-MB-231 ± paclitaxel normalized to alive cells at acquisition start (0 hours). Data are represented as the mean ± SEM. Statistical differences were assessed by the Wilcoxon matched-pair signed-rank test.
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from An Extracellular Matrix–Producing Subset of Cancer-Associated Fibroblasts Drives Chemoresistance in Breast Cancer via SRC Activation and G0S2 Upregulation
Primary ECM-myCAFs display a heterogeneous response to doxorubicin. A and B, Representative images of ECM-myCAFs from patient #2 (A) and patient #3 (B) ± doxorubicin at acquisition start (0 hours) and 72 hours after culture in ToC. Scale bar, 100 μm. White arrows, living cells; red arrows, dead cells. C, ECM-myCAF (from three different patients) apoptosis rate ± MDA-MB-231 ± doxorubicin (n = 3 independent experiments; n = 3 videos per condition). D, Alive ECM-myCAF (from three different patients) ± MDA-MB-231 ± doxorubicin normalized to alive cells at acquisition start (0 hours; n = 3 independent experiments; n = 3 videos per condition). E and F, ECM-myCAF apoptosis rate and alive cells (combining the three patients) ± MDA-MB-231 ± doxorubicin. G, Representative images of ECM-myCAFs under paclitaxel treatment at acquisition start (0 hours) and 72 hours after culture in ToC. Scale bar, 100 μm. White arrows, living cells; red arrows, dead cells. H, Manual quantification of ECM-myCAF apoptosis rate (combining three patients) ± MDA-MB-231 ± paclitaxel. I, Alive ECM-myCAF (combining three patients) ± MDA-MB-231 ± paclitaxel normalized to alive cells at acquisition start (0 hours). Data are represented as the mean ± SEM. Statistical differences were assessed by the Wilcoxon matched-pair signed-rank test.
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from An Extracellular Matrix–Producing Subset of Cancer-Associated Fibroblasts Drives Chemoresistance in Breast Cancer via SRC Activation and G0S2 Upregulation
G0S2 expression is elevated in cancer cells following direct ECM-myCAF co-culture in 2D conditions
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from An Extracellular Matrix–Producing Subset of Cancer-Associated Fibroblasts Drives Chemoresistance in Breast Cancer via SRC Activation and G0S2 Upregulation
G0S2 expression is elevated in cancer cells following direct ECM-myCAF co-culture in 2D conditions
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Video S7 from An Extracellular Matrix–Producing Subset of Cancer-Associated Fibroblasts Drives Chemoresistance in Breast Cancer via SRC Activation and G0S2 Upregulation
ToC mono-culture of MDA-MB-436, time length 72h, no treatment. Scale bar = 100 μm.
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessVideo S7 from An Extracellular Matrix–Producing Subset of Cancer-Associated Fibroblasts Drives Chemoresistance in Breast Cancer via SRC Activation and G0S2 Upregulation
ToC mono-culture of MDA-MB-436, time length 72h, no treatment. Scale bar = 100 μm.
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Figure 2 from An Extracellular Matrix–Producing Subset of Cancer-Associated Fibroblasts Drives Chemoresistance in Breast Cancer via SRC Activation and G0S2 Upregulation
Primary ECM-myCAFs protect TNBC cell lines from death under doxorubicin and paclitaxel treatment in a 3D ToC model. A, Schematic overview of 3D ToC generation from primary breast cancer–derived ECM-myCAF and TNBC cell lines. B, UMAP showing high expression of FAP+ CAF (also referred to as CAF-S1) and ECM-myCAF gene signatures (10) in ECM-myCAF, validating their identity after 3D ToC culture assessed by scRNA-seq (n = 9,651 cells from two independent experiments using two different patient-derived ECM-myCAFs). C, Representative images of MDA-MB-231 ± ECM-myCAF ± doxorubicin or paclitaxel treatment at acquisition start (0 hours) and 72 hours after culture in ToC. Scale bar, 100 μm. White arrows, cancer cells; yellow arrows, ECM-myCAFs. D, Manual quantification of live MDA-MB-231 ± ECM-myCAF ± doxorubicin normalized to live cells at acquisition start (0 hours; n = 3 independent experiments using three different patient-derived ECM-myCAFs; n = 3 videos per condition). E, Manual quantification of MDA-MB-231 apoptosis ± ECM-myCAF ± doxorubicin (n = 3 independent experiments using three different patient-derived ECM-myCAFs; n = 3 videos per condition). F and G, Automated quantification of MDA-MB-231 apoptosis index (F) and survival (G) ± ECM-myCAF ± doxorubicin (n = 4 independent experiments using four different patient-derived ECM-myCAFs; n = 3 videos per condition). H and I, Manual quantification of MDA-MB-231 apoptosis index (H) and survival (I) ± ECM-myCAF ± paclitaxel (n = 3 independent experiments using three different patient-derived ECM-myCAFs; n = 3 videos per condition). J and K, Automated quantification of MDA-MB-436 apoptosis index (J) and survival (K) ± ECM-myCAF ± doxorubicin (n = 2 independent experiments using two different patient-derived ECM-myCAFs; n = 3 videos per condition). L and M, Manual quantification of MDA-MB-436 apoptotic index (L) and survival (M) ± ECM-myCAF ± paclitaxel (n = 2 independent experiments using two different patient-derived ECM-myCAFs; n = 3 videos per condition). N, Representative images displaying typical ECM-myCAF and CAP fibroblast morphology. O and P, Automated quantification of MDA-MB-231 apoptosis index (O) and survival (P) ± CAP ± doxorubicin (n = 3 videos per condition). All data are represented as the mean ± SEM. Statistical differences were assessed by the Wilcoxon matched-pair signed-rank test. A, Created in BioRender. Mechta-Grigoriou, F. (2025) https://BioRender.com/fcjaht2.
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from An Extracellular Matrix–Producing Subset of Cancer-Associated Fibroblasts Drives Chemoresistance in Breast Cancer via SRC Activation and G0S2 Upregulation
Primary ECM-myCAFs protect TNBC cell lines from death under doxorubicin and paclitaxel treatment in a 3D ToC model. A, Schematic overview of 3D ToC generation from primary breast cancer–derived ECM-myCAF and TNBC cell lines. B, UMAP showing high expression of FAP+ CAF (also referred to as CAF-S1) and ECM-myCAF gene signatures (10) in ECM-myCAF, validating their identity after 3D ToC culture assessed by scRNA-seq (n = 9,651 cells from two independent experiments using two different patient-derived ECM-myCAFs). C, Representative images of MDA-MB-231 ± ECM-myCAF ± doxorubicin or paclitaxel treatment at acquisition start (0 hours) and 72 hours after culture in ToC. Scale bar, 100 μm. White arrows, cancer cells; yellow arrows, ECM-myCAFs. D, Manual quantification of live MDA-MB-231 ± ECM-myCAF ± doxorubicin normalized to live cells at acquisition start (0 hours; n = 3 independent experiments using three different patient-derived ECM-myCAFs; n = 3 videos per condition). E, Manual quantification of MDA-MB-231 apoptosis ± ECM-myCAF ± doxorubicin (n = 3 independent experiments using three different patient-derived ECM-myCAFs; n = 3 videos per condition). F and G, Automated quantification of MDA-MB-231 apoptosis index (F) and survival (G) ± ECM-myCAF ± doxorubicin (n = 4 independent experiments using four different patient-derived ECM-myCAFs; n = 3 videos per condition). H and I, Manual quantification of MDA-MB-231 apoptosis index (H) and survival (I) ± ECM-myCAF ± paclitaxel (n = 3 independent experiments using three different patient-derived ECM-myCAFs; n = 3 videos per condition). J and K, Automated quantification of MDA-MB-436 apoptosis index (J) and survival (K) ± ECM-myCAF ± doxorubicin (n = 2 independent experiments using two different patient-derived ECM-myCAFs; n = 3 videos per condition). L and M, Manual quantification of MDA-MB-436 apoptotic index (L) and survival (M) ± ECM-myCAF ± paclitaxel (n = 2 independent experiments using two different patient-derived ECM-myCAFs; n = 3 videos per condition). N, Representative images displaying typical ECM-myCAF and CAP fibroblast morphology. O and P, Automated quantification of MDA-MB-231 apoptosis index (O) and survival (P) ± CAP ± doxorubicin (n = 3 videos per condition). All data are represented as the mean ± SEM. Statistical differences were assessed by the Wilcoxon matched-pair signed-rank test. A, Created in BioRender. Mechta-Grigoriou, F. (2025) https://BioRender.com/fcjaht2.
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Video S4 from An Extracellular Matrix–Producing Subset of Cancer-Associated Fibroblasts Drives Chemoresistance in Breast Cancer via SRC Activation and G0S2 Upregulation
ToC co-culture of MDA-MB-231 with ECM-myCAF, time length 72h, 2μM Doxorubicin. Scale bar = 100 μm.
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessVideo S4 from An Extracellular Matrix–Producing Subset of Cancer-Associated Fibroblasts Drives Chemoresistance in Breast Cancer via SRC Activation and G0S2 Upregulation
ToC co-culture of MDA-MB-231 with ECM-myCAF, time length 72h, 2μM Doxorubicin. Scale bar = 100 μm.
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Video S1 from An Extracellular Matrix–Producing Subset of Cancer-Associated Fibroblasts Drives Chemoresistance in Breast Cancer via SRC Activation and G0S2 Upregulation
ToC mono-culture of MDA-MB-231, time length 72h, no treatment. Cancer cells are stained in red, cells turning green indicate apoptotic cells. Scale bar = 100 μm.
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessVideo S1 from An Extracellular Matrix–Producing Subset of Cancer-Associated Fibroblasts Drives Chemoresistance in Breast Cancer via SRC Activation and G0S2 Upregulation
ToC mono-culture of MDA-MB-231, time length 72h, no treatment. Cancer cells are stained in red, cells turning green indicate apoptotic cells. Scale bar = 100 μm.
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Video S15 from An Extracellular Matrix–Producing Subset of Cancer-Associated Fibroblasts Drives Chemoresistance in Breast Cancer via SRC Activation and G0S2 Upregulation
ToC mono-culture of primary ECM-myCAFs (sensitive, from patient #2), time length 72h, 2μM Doxorubicin. Scale bar = 100 μm.
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessVideo S15 from An Extracellular Matrix–Producing Subset of Cancer-Associated Fibroblasts Drives Chemoresistance in Breast Cancer via SRC Activation and G0S2 Upregulation
ToC mono-culture of primary ECM-myCAFs (sensitive, from patient #2), time length 72h, 2μM Doxorubicin. Scale bar = 100 μm.